Untitled

Bollito, E.; Berruti, A.; Bellina, M.; Mosca, Alessandra; Leonardo, E.; Tarabuzzi, R.; Cappia, S.; Mari, M.; Tampellini, M.; Fontana, D.; Gubetta, L.; Angeli, A.; Dogliotti, L.

doi:10.1023/a:1012463128084

Cited by 16 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results from the screening cohort identified an elevated serum CGA level was adversely associated with overall survival, limited to the subset of men with CRPC with GS ≥8. Prostatic adenocarcinomas with higher Gleason scores have a greater likelihood of neuroendocrine differentiation ( 9 , 17 ), providing rationale for our hypothesis that elevated serum CGA might be a useful marker in this subset of patients based on correlation with poor survival especially. We validated the prognostic value of serum CGA in men diagnosed initially with GS ≥8 in an independent cohort of men with CRPC.…”

Section: Discussionmentioning

confidence: 98%

Serum chromogranin-A-based prognosis in metastatic castration-resistant prostate cancer

Giridhar

Sanhueza

Hillman

et al. 2018

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

ObjectiveTo determine the prognostic value of serum chromogranin-A (CGA) in a two-cohort study of men with metastatic castrate resistant prostate cancer (mCRPC) and to compare with circulating tumor cells (CTCs) based prognosis.Patients and methodsA two cohort based evaluation for serum CGA for prognostication in CRPC stage was performed using a screening cohort of 256 men with mCRPC and an independent validation cohort of 92 men with mCRPC. In both cohorts, men receiving proton pump inhibitors and those with non-castrate levels of testosterone (>50 ng/dl) were excluded. Serum CGA was measured in a homogeneous automated immunofluorescent assay using time-resolved amplified cryptate emission. In the validation cohort, CTC enumeration was also performed using the FDA cleared CELLSEARCH®CTC test. Cox proportional hazard regression models were used for prognostic association of serum CGA and CTC counts with overall survival.ResultsIn the screening cohort 200 men were eligible for analysis. The median serum CGA was 100.3 ng/mL (interquartile range 67–161.3) and 34/200 were above the reference range. In the subset of men with Gleason scores ≥ 8, elevated CGA was associated with shorter overall survival [hazard ratio (HR) 2.19, p = 0.017]. In the validation cohort for 71 men eligible for analysis the median serum CGA was 90 ng/mL (interquartile range 55–156) and 31/71 patients had an elevated CGA. 51% of patients had a Gleason score ≥8 and 66/71 patients had CTCs enumerated with 26/66 with a CTC count ≥ 5 per 7.5ml blood sample (unfavorable). Both elevated serum CGA (HR 1.91, p = 0.043) and unfavorable CTC counts (HR 2.97, p = 0.0012) were adversely associated with overall survival and patients with ≥ 5 CTCs and elevated serum CGA had the shortest overall survival (HR 3.76, p = 0.008).ConclusionElevated serum CGA was negatively associated with OS in men with mCRPC. Serum CGA represents a prognostic biomarker that may complement CTC enumeration.

show abstract

Section: Discussionmentioning

confidence: 98%

Serum chromogranin-A-based prognosis in metastatic castration-resistant prostate cancer

Giridhar

Sanhueza

Hillman

et al. 2018

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

show abstract

“…However, in this trial the PSA level was monitored every 2–3 months, whereas the kinetics of serum PSA analyzed monthly during the first few months of abiraterone is associated with PSA flare in nearly 10% of these patients, which could impair the early evaluation of PSA response [ 16 ], The impact of FCH-PET/CT could be even more relevant for CRPC with no reliable serum biomarker, as is the case of bulky metastatic disease with low serum PSA levels. However, in a few of these cases, elevated circulating Chromogranin A levels have been reported as possible expression of a CRPC with neuroendocrine differentiation in which the role of FCH-PET/CT is not known [ 17 , 18 ]. Thus, the integrated use of PSA and FCH-PET/CT could potentially lead to a significant improvement in outcome prediction and in the therapeutic monitoring of CRPC patients.…”

Section: Discussionmentioning

confidence: 99%

“…However, the early FCH-PET/CT bone flare phenomenon should be considered as a limitation ofits utility as an early indicator marker, or thefirst follow-up FCH-PET/CT should be carried out 3 months after the start of therapy. Moreover, FCH uptake may be influenced by several factors, including the number of viable cells per unit volume, the tumor vascular supply, the sites of metastases and the neuroendocrine differentiation [ 17 , 18 , 26 , 27 ]. Recently, new PET tracers such as radiolabeled dihydrotestosterone and radiolabeled antibody to prostate-specific membrane antigen (PSMA) have shown great potential for assessing patients' early biologic response to hormonal therapies in prostate cancer [ 28 – 30 ].…”

Section: Discussionmentioning

confidence: 99%

Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone

et al. 2014

View full text Add to dashboard Cite

Objective: We investigated the role of 18F-fluorocholine positron emission tomography/computed tomography (FCH-PET/CT) in the early evaluation of abiraterone and outcome prediction in patients with metastatic castration-resistant prostate cancer (CRPC).Patient and methods: Forty-three patients with metastatic CRPC progressing after docetaxel received abiraterone 1,000 mg daily with prednisone 5 mg twice daily. Patients were evaluated monthly for serological PSA response and safety. FCH-PET/CT was done at baseline and after 3 to 6 weeks. Univariate and multivariate Cox regression models addressed potential predictors of progression-free survival (PFS) and overall survival (OS).Results: Declines in PSA level of ≥50% were seen in 21 of 43 (49%) patients. Forty-two patients were evaluable for FCH-PET/CT response. FCH-PET/CT bone flare was observed in 4 of 42 (10%) evaluable patients. In univariate analysis, PSA decline and FCH-PET/CT response predicted PFS, while PSA decline and FCH-PET/CT (progression vs non progression) predicted OS. In multivariate analysis, only FCH-PET/CT (progression vs nonprogression) remained significant for PFS and OS (p = 0.022 and p = 0.027, respectively).Conclusion: Early FCH-PET/CT can predict clinical outcome in CRPC beyond PSA response. These data support further studies on FCH-PET/CT for abiraterone monitoring and outcome prediction in patients with CRPC.

show abstract

Expression of serotonin receptors and role of serotonin in human prostate cancer tissue and cell lines

et al. 2004

View full text Add to dashboard Cite

This is the first study demonstrating an overexpression of 5-HTR subtypes 1A and 1B in PC cells, especially in high-grade tumors. Moreover, 5-HT stimulates proliferation of PC cells and 5-HTR1A antagonists inhibit proliferation. Thus, we propose that 5-HT has an important role in tumor progression, especially in the androgen-independent state of the disease. The design of specific antagonists for this type of receptor might be useful for the growth control of androgen-independent tumors.

show abstract

Untitled

Abstract: These data support the concept that NE differentiation in human prostate cancer has a negative prognostic significance. Circulating CgA levels reflect immunohistochemical findings.

Cited by 16 publications

References 0 publications

Serum chromogranin-A-based prognosis in metastatic castration-resistant prostate cancer

Serum chromogranin-A-based prognosis in metastatic castration-resistant prostate cancer

Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone

Expression of serotonin receptors and role of serotonin in human prostate cancer tissue and cell lines

Contact Info

Product

Resources

About